~ T3D Therapeutics, Inc. has recently announced the addition of Dr. Robert Alexander to their Scientific Advisory Board. Dr. Alexander, a leading expert in Alzheimer's disease (AD) drug development and regulatory affairs, brings a wealth of knowledge and experience to the clinical stage drug development company.

Currently serving as the Chief Scientific Officer of the Alzheimer's Prevention Initiative at the Banner Alzheimer's Institute and a Research Professor at the University of Arizona School of Medicine – Phoenix, Dr. Alexander has held various positions in the pharmaceutical industry. He has served as VP in the neuroscience therapeutic area unit at Takeda, VP and head of clinical for neuroscience and pain at Pfizer, VP of clinical for CNS and pain innovative medicines unit (iMed) at AstraZeneca, as well as other positions in discovery medicine and neuroscience at GSK and Merck.

With an M.D. degree from The University of Chicago Pritzker School of Medicine and certification from the American Board of Psychiatry and Neurology, Dr. Alexander specializes in psychopharmacology and has conducted or supervised clinical studies in a wide range of neurologic and psychiatric indications.

More on The Arizonar

• K2 Integrity and Sonata One Partner to Accelerate Capital Raising, Reduce Risk, and Deliver Scalable Advisory Services for Private Fund Managers
• The World's No.1 Superstar™ Walks Where Legends Rest: A Sacred Encounter in Rome Before the Pope's Passing
• Plumbing Services in Queen Creek
• Coming Up on "Financial Freedom with Tom Hegna" Financial Expert Parker Faulkner
• Tobu Railway Announces a Price Revision on the "NIKKO PASS All Area" and "NIKKO PASS World Heritage Area," from April 20, 2025

T3D Therapeutics' CEO John Didsbury expressed his excitement about having Dr. Alexander on board, stating that his expertise will be invaluable as they advance their drug candidate T3D-959 beyond their completed Phase 2 PIONEER trial.

In response to joining T3D Therapeutics' Scientific Advisory Board, Dr. Alexander shared his enthusiasm for the potential impact that T3D-959 could have on AD patients based on its compelling Phase 2 results in mild-to-moderate cases. He also expressed his commitment to helping expedite the drug's journey to market.

T3D-959 is a small molecule that is delivered orally once daily and acts as a brain-penetrating PPAR delta/gamma dual nuclear receptor agonist. It is designed to address both glucose and lipid metabolism dysfunctions, which are present in AD and other neurodegenerative disorders.

T3D Therapeutics, Inc. is a privately held company based in Research Triangle Park, NC. They hold an exclusive license for T3D-959, their lead product candidate, and a platform of related molecules. The company's mission is to develop and commercialize T3D-959 for the treatment of Alzheimer's disease.

With the addition of Dr. Alexander to their team, T3D Therapeutics is well-positioned to continue their efforts towards finding a new orally administered treatment for AD. His expertise and experience will undoubtedly be instrumental in advancing T3D-959 towards its goal of providing relief to those suffering from this devastating disease.

---

Show All News | Report Violation